PD-1 Inhibitors Raise Survival in NSCLC

Bristol-Myers Squibb’s nivolumab and Merck’s MK-3475, investigational monoclonal antibodies that inhibit the immune checkpoint receptor PD-1 expressed on activated T cells, have demonstrated positive results in phase I trials of previously treated patients with non–small cell lung cancer (NSCLC). The results were reported at the World Conference on Lung Cancer in Sydney, Australia, on October 29.

In a trial of nivolumab among various solid tumors, first reported in 2012, follow-up of an expanded NSCLC cohort across all dosages showed a 1-year survival rate of 42% and a 2-year survival rate of 24%. Median overall survival of 9.9 months was similar for squamous and nonsquamous NSCLC cases. The overall rate of objective response to met RECIST criteria was 17%, the company said, with activity across a broad range of patients including those with common mutations such as EGFR and KRAS. Side effects were similar to those previously reported for the trial, with 5% of patients experiencing grade 3 or 4 adverse events.

“These are encouraging phase I results from the expanded cohort of patients with lung cancer, the leading cause of cancer deaths globally,” said Michael Giordano, senior vice president and head of development for oncology and immunology at Bristol-Myers Squibb. “We are seeking to confirm these early data in ongoing phase III trials.”

In addition to NSCLC trials, nivolumab will be studied as a monotherapy and in combination with other therapies in trials in gastric cancer, hematologic cancer, hepatocellular carcinoma, melanoma, pancreatic cancer, renal cell carcinoma, small cell lung cancer, and triple-negative breast cancer.

Also at the conference in Sydney, Merck presented interim data from a phase Ib trial with a cohort of 38 previously treated NSCLC patients who received MK-3475. Investigator-assessed immune-related response (IRRC) showed a rate of 24%, while 21% of patients met RECIST response criteria. Among all patients, median overall survival was just under a year. Most adverse events were low grade, with one incident of grade 3 pulmonary edema.

Additionally, an initial analysis found high levels of expression of PD-L1 (the PD-1 ligand that may be expressed at high levels in certain cancer cells) in six of nine patients who met the IRRC criteria. This suggests that PD-L1 measurement "has the potential to be a useful predictor of response to MK-3475,” said Eric Rubin, MD, vice president of oncology at Merck Research Laboratories.

The company is going ahead with a phase II/III trial comparing two doses of MK-3475 to standard docetaxel therapy for previously treated patients with NSCLC lung cancer.

Overall, eight clinical trials are under way with MK-3475, for patients with bladder cancer, colorectal cancer, gastric cancer, head and neck cancer, hematologic malignancies, NSCLC, and triple-negative breast cancer, the company said. Additional trials, both as monotherapy and in combination with other cancer therapies, are being planned.

Ariad Suspends Ponatinib Sales

Citing serious cardiovascular side effects, the U.S. Food and Drug Administration (FDA) asked Ariad Pharmaceuticals of Cambridge, MA, to temporarily suspend sales and marketing of ponatinib (Iclusig) to treat chronic myeloid leukemia (CML) in patients resistant to first-line therapy.

The FDA’s October 31 request to suspend sales of ponatinib—which received accelerated approval in December 2012—followed an ongoing FDA investigation into serious arterial thrombotic events reported during the single-arm phase II PACE trial, which enrolled CML patients who failed to respond to imatinib (Gleevec; Genentech) or carried the T315I mutation. At the time of the request, FDA investigators reported an increased frequency of serious adverse vascular events since the drug was approved, with 24% of patients enrolled in the phase II PACE trial (median treatment 1.3 years) and 48% of patients in the...
phase I PACE trial (median treatment 2.7 years) experiencing such events. In an analysis of the phase II study, performed in November 2012 with a median follow-up of 15 months and published in the New England Journal of Medicine, researchers initially reported a 7.6% rate of patients with serious adverse arterial thrombosis events [N Engl J Med 2013;369:1783–96]. That rate prompted a boxed warning for these side effects when the drug was approved. After the overall rate of serious adverse vascular events rose in subsequent months, Ariad suspended the PACE trial and terminated the phase III EPIC trial, a first-line randomized trial of ponatinib versus imatinib. The FDA says it will continue to evaluate ponatinib in order to determine whether the benefits may outweigh the risks for some patient populations. Patients enrolled in the trial who benefited from ponatinib may continue treatment under an emergency Investigational New Drug application filed by their physician.

“We know that cardiovascular risk is an evolving problem with cancer patients as you deal with problematic populations who have been previously treated,” says Christopher-Paul Milne, DVM, MPH, JD, director of research at the Tufts Center for the Study of Drug Development in Boston, MA. “Whatever underlying cardiovascular risk there was may be increased with second- and third-line agents.”

Despite the significant risk of adverse events with ponatinib, suspension might have been avoided under a better system for monitoring and reporting adverse events, says Javid Moslehi, MD, codirector of the cardio-oncology program at Dana-Farber Cancer Institute in Boston.

“Currently, National Cancer Institute criteria for reporting adverse events with cancer drugs are different than ones used for other classes of drugs such as cardiovascular drugs, compromising the detection of cardiotoxicity,” says Moslehi, who coauthored a perspective on the PACE study findings [N Engl J Med 2013;369:1779–81]. “If we know the root of the problem we can address it,” he says. “It could be because of rapidly progressing atherosclerosis, and it could be very helpful if you treat those patients with a statin.”

Similarly, patients with arterial clots might be pretreated with aspirin or the blood clot preventer Plavix (clopidogrel, Bristol-Myers Squibb and Sanofi), and those with vasospasm could be started on nitrates to open up the arteries.

“The suspension of ponatinib also raises questions about whether the accelerated approval process exposes patients to excessive risk. However, it appears as if the process worked well in this case, says Milne.

“This issue only came to the FDA’s attention a few weeks ago, and they acted on it quickly,” he says. “It shows that they are increasing the ways they can make decisions in the post-marketing scenario.”

**Strategic Plan Aims to Curb Drug Shortages**

The U.S. Food and Drug Administration (FDA) has released a strategic plan to strengthen its response to imminent and existing drug shortages, as well as a proposed rule requiring manufacturers of drugs and biologics to alert the agency to the impending discontinuation of any products or interruptions in manufacturing that could deplete supply.

The “Strategic Plan for Preventing and Mitigating Drug Shortages,” released on October 31, explains that early notification of manufacturing disruptions gives the FDA time to work with drug companies to help resolve such disruptions, identify other companies that might be able to increase production, and expedite inspections and reviews of product submissions from drugmakers that might help prevent or ease shortages.

The plan also calls for incentives for manufacturers to improve the quality of their drugs and facilities.

“The FDA can only do so much,” says Erin Fox, PharmD, director of the drug information service at University of Utah Health Care in Salt Lake City. “We know that many of the ongoing problems are related to poor manufacturing quality and companies not investing in their factories over time.”

One manufacturer, Ben Venue Laboratories in Bedford, OH, announced in October that it would permanently cease all drug production by the end of 2013. The company had halted production and spent more than $350 million since 2010 to repair and upgrade its facilities, but declared that the ongoing investment needed to overcome its challenges is too great for it to continue.

“That took away some of the hope that some of the shortages are going to be resolved quickly,” says Fox. She notes that Ben Venue was the only U.S. manufacturer of thiopeta, which is used to treat ovarian, breast, and bladder cancers and lymphomas. For now, the FDA is allowing an imported replacement, the brand-name drug Tepadina from Italian drugmaker Adrienne, although the logistics of purchasing it further complicate the situation.

The proposed rule, released on the same day as the strategic plan, implements the early notification requirements included in the 2012 Food and Drug Administration Safety and Innovation Act. It requires manufacturers to alert the agency about potential drug shortages at least 6 months prior to permanently discontinuing a drug or interrupting its production. If that isn’t possible, manufacturers should do so “as soon as practicable” but no later than 5 days after the disruption. The proposed rule also spells out the types of products covered and the information to be reported.

Unlike an interim rule currently in force, the proposed rule would extend to manufacturers of biologic products, such as monoclonal antibody products and vaccines.

Janis Abkowitz, MD, president of the American Society of Hematology, applauded the inclusion of both drugs and biologics in the proposed rule. Shortages, she says, have been particularly troublesome for hematologists because “many of the drugs most vulnerable to shortages—older, generic sterile injectables—are used to treat blood disorders,” including cancer.

Early alerts about possible disruptions in drug supplies since 2011 have helped prevent some shortages. In 2012, shortages of more than 280 drugs were averted, and reports of new shortages dropped to 117, from 250 the previous year.

At the end of September, says Fox, 294 drugs were in short supply, 31 of which were cancer drugs.
Ariad Suspends Ponatinib Sales


Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-NB2013-163

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.